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Objective: To evaluate the parameters associated with significant gastrointestinal (GI) involvement in Henoch-Schönlein
Purpura (HSP), and construct a scoring system for the identification of patients at high risk of gross blood
in stools.
Study design: Data for HSP patients hospitalized at each of seven institutes were retrospectively analyzed.
Patients were divided into four groups according to the consequent severity of GI involvement. Identification
of laboratory parameters at the time of admission were then used to differentiate the groups, and a scoring
system to predict gross intestinal bleeding was constructed. Prognostic efficiency, correlation with the
subsequent duration of abdominal pain, and association with manifestations excluding abdominal pain were
also analyzed.
Results: An analysis of variance (ANOVA) test showed significant intergroup differences in white blood cell (WBC)
count, neutrophil count, serum albumin, potassium, plasma D-dimer and coagulation factor XIII activity. A scoring
system consisting of these parameters showed a good prognostic value for gross intestinal bleeding in a receiver
operating characteristic (ROC) analysis, and a cut-off value of 4 points showed a sensitivity of 90.0% and specificity
of 80.6%. The score was also correlated with the duration of abdominal pain after admission. A significantly higher
score (s) was observed in patients presenting with nephritis, although the predictive value was poor.
Conclusion: A scoring system consisting of generally available parameters was of use in predicting severe GI
involvement in HSP patients. Although further study is needed, initial therapy in accordance with disease activity
may be taken into consideration using this scoring system.Introduction
Henoch-Schönlein Purpura (HSP) is a systemic, IgA-
mediated, small vessel vasculitis which is common in
children (Saulsbury 2001). Clinical manifestations inclu-
ding non-thrombocytopenic purpura, gastrointestinal
(GI) involvement and arthralgia are common in the early
phase of HSP. Further, HSP nephritis (HSPN), the onset
of which may be delayed for weeks or months after the
appearance of other symptoms, is the most serious* Correspondence: ntsune5p@asahikawa-med.ac.jp
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in any medium, provided the original work is plong-term complication of HSP (Narchi 2005). Al-
though HSP generally follows a benign, self-limiting
course that is resolved within a few weeks, some cases
present with severe GI involvement including massive
intestinal bleeding that can lead to acute complications
such as intestinal perforation or obstruction (Choong &
Beasley 1998; Saulsbury 2007). Severe GI involvement
presenting as gross blood in stools in the early phase of
HSP is important, not only because of the distress it
causes patients, but also because it is a significant risk
factor for the subsequent onset of HSPN (Kaku et al.
1998; Sano et al. 2002; Bogdanovic 2009). However, the
assessment of GI involvement can be often difficult dueis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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often fluctuates, and the common presentation of blood
in stools can be delayed for several days after the onset
of other symptoms (Zhang & Huang 2008).
Previous reports have already demonstrated that HSP
patients present with a high serum IgA concentration
(Saulsbury 1999; Calvino et al. 2001; Trapani et al. 2005),
low C3 or C4 (Calvino et al. 2001; Trapani et al. 2005), and
leukocytosis (Trapani et al. 2005). Furthermore, a decrease
in fXIII activity (Kamitsuji et al. 1987), and increases in pro-
thrombin fragment 1 + 2 and D-dimer levels (Yilmaz et al.
2005) were shown to be associated with the severity of GI
involvement. Unfortunately, however, the sole predictive
value of these parameters for intestinal bleeding has not yet
been demonstrated.
In the present study, we conducted a multi-centered
retrospective analysis of 140 patients with HSP to
evaluate the parameters associated with significant GI
involvement, and construct a scoring system for the
identification of patients at high risk for such
















Duration from symptom onset to admission







Significant correlation: HSPN vs Male (R =
GI groups were categorized as follows; Group I: no abdominal pain, Group II: abdom
fecal hemoglobin, but negative for gross blood in stools, and Group IV: presence ofPatients and methods
The study was performed in accordance with the ethical
standards laid down in the Declaration of Helsinki
principles.
Study population
We retrospectively reviewed the medical records of
HSP patients hospitalized between January 2003 and
December 2012 at seven institutions in Hokkaido,
Japan. A diagnosis of HSP was made on the basis of
the presence of the major manifestations of the ill-
ness, consisting of purpura and abdominal pain or
arthralgia without thrombocytopenia (Saulsbury 1999).
HSPN was defined by the presence of gross or micro-
scopic hematuria (>5 cells per high power field from
a centrifuged specimen) either with or without pro-
teinuria (Saulsbury 1993). Patients were excluded on
the basis of severe complications affecting abdominal
pain or a lack of laboratory data. Patients represent-
ing with abdominal pain later than two days after
hospitalization were also excluded, in consideration ofent (GI) groups











Group I Group II Group II Group IV
57 24 21 11
6 (1-15) 5.5 (2-13) 7 (2.-10) 6 (2-11)
5.8 ± 5.6 5.4 ± 4.4 5.5 ± 5.5 7.5 ± 4.7
55 (100%) 23 (100%) 20 (100%) 10 (100%)
26 (46%) 7 (29%) 11 (52%) 4 (36%)
- 23 (100%) 20 (100%) 10 (100%)
11 (19%) 3 (13%) 4 (19%) 0 (0%)
9 (15%) 15 (63%) 17 (81%) 10 (90%)
5 (9%) 8 (33%) 4 (19%) 3 (27%)
0.35, p = <0.01)
inal pain without fecal hemoglobin, Group III: abdominal pain and positive for
gross blood in stools.
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tivity. Fecal hemoglobin was repetitively examined as
long as abdominal pain continued. The duration of
abdominal pain after admission was defined as the
number of hospitalization day(s) the patient suffered
from abdominal pain without remission for a 24-hour
interval.Therapeutic strategy for early phase HSP
The essential therapeutic strategy for early phase HSP on
admission was basically concordant among the participating(A)
(B)
Figure 1 Parameters showed overall differences among GI groups and c
serum albumin, potassium, plasma D-dimer and coagulation factor XIII levels i
differences by an analysis of variance (ANOVA) test. The probability values in th
Mann–Whitney U test between consecutive groups. Bars in the graph represe
system consisting of the above parameters (left) and scores at the time of
in the graph is for the ANOVA test, and that below the graph are for the M
graph represents the 10th, 25th, median, 75th, and 95th percentiles.institutes in that patients were recommended bed rest, and
oral or intravenous prednisolone (PSL) 1.5 ~ 2 mg/kg/day
was administrated when the patient complained of
unacceptable abdominal or joint pain.Four patient groups categorized according to
gastrointestinal involvement
Patients were divided into four groups based on the se-
verity of gastrointestinal (GI) involvement as follows;
Group I: no abdominal pain, Group II: presence of
abdominal pain, without intestinal bleeding (negativeonstruction of a scoring system. (A) WBC count, neutrophil count,
n each GI group are shown. These parameters showed overall significant
e graph are for the ANOVA test, and those below the graph are for the
nts the 10th, 25th, median, 75th, and 95th percentiles. (B) The scoring
admission for each GI group (right) are shown. The probability value
ann–Whitney U test between consecutive GI groups. Bars in the
Table 2 The average and standard deviation of each parameter and the scores for the GI groups are shown
mean ± SD Group I Group II Group III Group IV P value
WBC count (/μl) 8938 ± 3057 9575 ± 3821 10575 ± 2993 13808 ± 4634 0.004
neutrophil count (/μl) 5068 ± 2626 6716 ± 3661 7324 ± 3147 10450 ± 3879 0.001
Albumin (g/dl) 4.22 ± 0.3 4.19 ± 0.5 4.06 ± 0.4 3.64 ± 0.5 0.020
D-dimer (μg/dl) 3.72 ± 3.6 6.22 ± 9.1 8.75 ± 9.0 11.75 ± 6.56 0.012
Coagulation factor XIII (%) 87.34 ± 26.5 87.80 ± 24.3 72.12 ± 25.2 57.48 ± 34.7 0.001
Sodium (mEq)l 138.86 ± 2.1 138.39 ± 2.0 137.36 ± 2.1 136.5 ± 2.3 0.044
Score Point(s) 1.47 ± 1.5 2.17 ± 1.8 3.20 ± 2.1 5.8 ± 2.4 <0.001
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positive for fecal hemoglobin, but not presenting with
gross blood in the stools, and Group IV: abdominal pain
with gross blood in the stools.
Data analysis
All analyses were carried out using the SPSS statistical
software package, version 16.0 (SPSS, Chicago, IL, USA).
Data are presented as the mean ± standard deviation (SD)
or median and range for continuous variables, or as the
percentage of patients showing a given categorical vari-
able. For all analyses, a 2-sided probability value below
0.05 was considered to indicate statistical significance.
Spearman’s rank correlation coefficient test was used
to examine correlations among categorical parameters
among the baseline characteristics and GI-involvement
groups. A Kruskal-Wallis analysis of variance (ANOVA)
was used to examine overall differences in laboratory
data at the time of admission and other continuous
variables among the GI-involvement groups. The data
included WBC count, neutrophil count, hemoglobin,
platelet count, serum concentration of albumin, aspar-
tate aminotransferase (AST), alanine aminotransferase
(ALT), lactate dehydrogenase (LDH), and C-reactive(A)
Figure 2 Prognostic accuracy of scoring system for gross blood in stool
patients with gross blood in stools. (B) ROC curves and the areas under the RO
shown. The longitudinal axis shows the sensitivity for WBC count, neutrophil cprotein (CRP), prothrombin time (PT), activated partial
thromboplastin time (APTT), plasma concentration of
fibrinogen and D-dimer, coagulation factor XIII (fXIII) ac-
tivity, serum concentration of antistreptolysin O antibody
(ASO), IgA, complement C3, C4, total hemolytic comple-
ment (Ch50), sodium, and potassium. And age, days
from symptom onset to admission, and days from ab-
dominal pain onset to admission was also extracted.
We then constructed a scoring model with which to
identify severe GI involvement consisting of the pa-
rameters found to be statistically significant in the
ANOVA analysis. A receiver operating characteristic
(ROC) analysis was also carried out to examine the
diagnostic utility of the constructed scoring model,
and the Mann–Whitney U test was used to compare
scores between patients with and without arthralgia and
nephritis. The correlation between duration of abdominal
pain after admission and score at admission was also
examined using Spearman’s rank correlation coefficient.
Results
Patient characteristics
During the study period, 140 patients were analysed, with
27 later excluded (due to complications of intussusception(B)
. (A) Receiver operating characteristic (ROC) curves of the scores for
C curves (AUCs) for each parameter comprising the scoring system are















Duration of Pain after admission (Days)
Patients received PSL for abdominal pain (n=43)
Figure 3 Association between initial score and subsequent duration of abdominal pain. Scatter plots of scores at the time of admission
(longitudinal axis) and the subsequent duration of abdominal pain (horizontal axis) in 43 patients who received PSL therapy due to abdominal
pain are shown.
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data in 19, and presentation of abdominal pain later than
two days after admission in 3 patients). Thus, 113 patients
were included in the study. Table 1 shows the baseline
characteristics of the patients by GI-involvement group.
Although a significant correlation was observed between
the development of HSPN and gender, with males more






















Figure 4 Comparison of scores by HSP manifestations except for abd
(A) arthralgia (mean ± SD; 1.97 ± 1.94 and 2.38 ± 2.44, respectively) or (B)found among GI-involvement groups for any of the
patient characteristics.Construction of a scoring system for the diagnosis of
severe gastrointestinal involvement
An ANOVA test showed the presence of significant over-


















ominal pain. Scores compared between patients with and without
nephritis (average ± SD; 3.31 ± 1.89 and 2.15 ± 2.25, respectively).
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D-dimer, and fXIII activity among the GI groups
(Figure 1A). Construction of a scoring model consisting
of these parameters was then carried out to increase
prognostic utility (Figure 1B). The mean ± SD of each
parameter and score(s) are shown in Table 2. Subse-
quently, ROC curves for Group IV were also evaluated
(Figure 2). The area under the ROC curve (AUC) of
score(s) for Group IV patients demonstrated good prog-
nostic accuracy (AUC = 0.892). The construction of a
scoring model improved diagnostic accuracy in com-
parison to that of each sole parameter in terms of
AUC. To identify Group IV patients, the cut-off value
was set at 4 points, a value which showed 90.0% sensi-
tivity and 78.4% specificity.
Association between initial score and subsequent
duration of abdominal pain
In the study population, 56 patients (49%) presented
with abdominal pain, placing them into Group II ~ IV,
and 43 of them (76%) received PSL at 1.5 ~ 2 mg/kg/day.
The scores at the time of admission for the 43 patients
who received PSL for abdominal pain were significantly
correlated with the subsequent duration of abdominal
pain after admission (Figure 3).
Association between initial score and subsequent
development of HSPN
A comparison of scores in association with manifestations
of HSP excluding abdominal pain was also undertaken
(Figure 4). There was no difference in scores between pa-
tients with or without arthralgia. A higher score was ob-
served in patients with subsequent presentation of HSPN.
However, the AUC for HSPN score showed only poor
prognostic accuracy (AUC = 0.67, the ROC curve is not
shown).
Discussion
We focused on the prediction of significant GI involve-
ment in the early phase of HSP, and found that our sco-
ring system, consisting of generally available laboratory
parameters, may be of value. A score of 4 points or higher,
at the time of admission showed a good predictive value
for gross blood in stools, and was associated with a longer
duration of abdominal pain under PSL treatment. Based
on its considerable predictive value for severe GI involve-
ment, our scoring system has the potential to determine
whether PSL intervention or supportive therapy, such
as temporal fasting, should be undertaken. Further, as
the monitoring of scores by repeat evaluation in several
patients showed sequential changes parallel with GI
symptoms (data not shown), it may also be useful for
clinical follow up.The precise mechanism underlying the changes in
the parameters comprising the scoring system has not
yet been clarified. Kawasaki disease, another systemic
vasculitis common in children, often presents as hypo-
natremia and hypoalbuminemia, especially in severe cases
(Fukunishi et al. 2000; Kobayashi et al. 2006). Further, pa-
tients with ulcerative colitis present with elevated D-dimer
levels (Alkim et al. 2011; Zezos et al. 2009) and decreased
fXIII activity (Lorenz et al. 1991), reflecting the inflam-
mation of and injury to the intestinal mucosa. In con-
sideration of these facts, our results might be regarded
as reflecting severe vasculitis and the subsequent de-
struction of the small vessels, resulting in massive injury
to the intestinal mucosa.
The efficacy of glucocorticoid therapy against the early
symptoms of HSP remains controversial to a point. Several
randomized controlled trials have reported that short-term
PSL therapy (1.5 ~ 2 mg/kg/day) reduces the intensity of
abdominal pain and arthralgia in early HSP (Ronkainen
et al. 2006; Chartapisak et al. 2009; Rosenblum & Winter
1987). However, there have been several patient reports
describing severe, persistent GI involvement despite ap-
propriate PSL therapy (Saulsbury 1999; Taylor et al.
1971). As the proportion of patients with severe GI in-
volvement is small, their refractoriness might be hidden
behind the majority of benign cases. However, in terms
of preventing HSPN, early identification and manage-
ment of this small proportion of patients with severe
GI involvement might be more important as, along with
persistent purpura (Kaku et al. 1998; Sano et al. 2002;
Rigante et al. 2005; Shin & Lee 2006; de Almeida et al.
2007), older age (Kaku et al. 1998; Sano et al. 2002; de
Almeida et al. 2007), and decreased fXIII activity (Kaku
et al. 1998; Sano et al. 2002), it is known to be an inde-
pendent risk factor for HSPN (Kaku et al. 1998; Sano
et al. 2002; Ronkainen et al. 2006; Shin & Lee 2006).
As current PSL therapy in early HSP does not prevent
subsequent HSPN (Ronkainen et al. 2006; Chartapisak
et al. 2009; Rosenblum & Winter 1987; Huber et al.
2004), we propose the future evaluation of novel thera-
peutic strategies according to disease activity, and our
scoring system might make an important contribution
to this evaluation.
Of course, our study has several limitations. Our defin-
ition of GI group classifications was dependent on sub-
jective symptoms and fecal examination; therefore, the
classification criteria might require some improvement
in terms of accuracy. Further, the proportion of patients
with gross blood in stools was small. Last, our study was
based on only a single cohort analysis. The survey of an-
other cohort of HSP of HSP patients using our scoring
system should help prove its validity. In addition, further
large-scale or prospective studies are needed to over-
come these limitations.
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The current study is the first report to the development
of a scoring system for the identification of patients at
risk for severe GI involvement on the basis of laboratory
tests in the early phase of HSP.
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